Compare Fox Corp Class A (FOXA) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Revvity Inc — how do they compare? Fox Corp Class A trades at $62.43 (market cap $25.36B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Fox Corp Class A is the larger of the two by market cap, and Fox Corp Class A pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Revvity Inc for 12 Days on average.
| FOXA | RVTY | |
|---|---|---|
Market Cap | $25.36B | $16.98B |
Volume | 2,566,954 | 1,456,900 |
Sector | Media | Health |
52-Week High | $76.11 | $157.36 |
52-Week Low | $48.79 | $82.26 |
Typical Hold Time | 34 Days | 12 Days |
Enterprise Value | $28.72B | $19.30B |
Dividend Yield | 0.91% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $62.41, down 0.46% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 16.3% revenue growth to $16.30B in 2025 and three consecutive quarterly earnings beats. The pending $22B Roku acquisition, currently under DOJ review, represents a major strategic development. Analyst consensus is bullish with a $72.00 price target and no sell ratings among 48 analysts.
The outlook is positive given strong earnings momentum, reasonable valuation (P/E 16.55), and potential upside from the Roku deal. Key risks include regulatory hurdles for the acquisition and a projected decline in 2026 net income. The stock offers a compelling risk-reward profile for investors seeking exposure to media consolidation.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
